Brief: Kymera Plans To Initiate A KT-621 Phase 1B Trial In Atopic Dermatitis Patients In 2Q25 With Data In 4Q25

Kymera Therapeutics

14/01/2025 12:43

Jan 14 (Reuters) - Kymera Therapeutics Inc  KYMR.O :
    * KYMERA: PLANS TO INITIATE A KT-621 PHASE 1B TRIAL IN
ATOPIC
DERMATITIS PATIENTS IN 2Q25 WITH DATA IN 4Q25
    * KYMERA: TO INITIATE PARALLEL PHASE 2B TRIALS IN AD AND
ASTHMA IN
LATE 2025 AND EARLY 2026, RESPECTIVELY
    * KYMERA: WELL-CAPITALIZED WITH $850 MILLION IN CASH AND
RUNWAY
INTO MID-2027

Source text:  ID:nGNX82lt7l 
Further company coverage:  KYMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))